Clinical Trial Update: The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous infusions of three doses of DG3173 on growth hormone levels in untreated acromegaly patients is completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• DG3173

Snippet

Sponsor: Aspireo Pharmaceuticals Limited | Conditions: Acromegaly | Phase 2 | Status: COMPLETED | Results posted: 2018-02-15